https://www.selleckchem.com/pr....oducts/ldn-212854.ht
This prospective longitudinal study quantifies health-related quality of life (HRQoL) up to 10 years following permanent iodine-125 ( I) prostate brachytherapy alone for localized prostate cancer. In total, 120 patients completed a validated expanded prostate cancer index composite (EPIC) questionnaire pre-treatment and at 8 time points after treatment (6 weeks, 6, 10, 18 months, and 2, 3, 5, 10 years). At each time point, clinically relevant small, moderate, and severe declines in HRQoL were defined as 0.2-0.5 SD, 0.5-0.8 SD, and &g
Like
Comment
Share
